NICE publishes final no for Eisai's Halaven
This article was originally published in Scrip
Executive Summary
Today's final guidance from NICE, the health technology appraisal institute for England and Wales, rejects Eisai's Halaven (eribulin) for locally advanced or metastatic breast cancer in patients whose disease has progressed after at least two chemotherapeutic regimens. The rejection comes after a failed appeal from Eisai against the final draft recommendations.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.